Destiny Pharma PLC (AIM:DEST) has highlighted the publication of a major Lancet study which determined that Antimicrobial Resistance (AMR) is one of the causes of death across the world.
The company’s XF platform is delivering effective drug candidates that also address the threat of AMR, with a Phase 2b trial recently completed and Phase 3 presently being planned.
In Lancet, the study highlighted that over one million deaths occurred in 2019 due to bacterial Antimicrobial Resistance (AMR).
"This report validates the very real clinical need and potential global commercial opportunity for our XF platform as it delivers clinical candidates that prevent infections whilst addressing the threat of AMR.
“The excellent results from our Phase 2b study demonstrate the potential of our XF-73 nasal gel to prevent post-surgical infections caused by S. aureus, such as MRSA, and we are focused on finalising the Phase 3 clinical trial plans.
“Additionally, we are testing XF-73 in two dermal infection preclinical programmes."